In this episode of The BioHub, I’m joined by Dr. Adam Mendelsohn, Co-Founder and CEO of Vivani Medical.
Adam’s journey spans bioengineering at UCSF and UC Berkeley to founding Nano Precision Medical and now leading Vivani following its 2022 merger. Vivani is developing long-term, sub-dermal drug implants designed to transform treatment for chronic diseases such as obesity and diabetes.
We discuss the science behind the platform, why long-acting implants could shift the treatment paradigm, what’s happening at Vivani right now, and what it takes to build and finance a biotech company in today’s market.